161 related articles for article (PubMed ID: 34887213)
21. CIC-Mediated Modulation of MAPK Signaling Opposes Receptor Tyrosine Kinase Inhibitor Response in Kinase-Addicted Sarcoma.
Odintsov I; Ortiz MV; Khodos I; Mattar MS; Lui AJW; Kohsaka S; de Stanchina E; Bender JLG; Ladanyi M; Somwar R
Cancer Res; 2022 Mar; 82(6):1110-1127. PubMed ID: 35074756
[TBL] [Abstract][Full Text] [Related]
22. NTRK and other recently described kinase fusion positive uterine sarcomas: A review of a group of rare neoplasms.
Croce S; Hostein I; McCluggage WG
Genes Chromosomes Cancer; 2021 Mar; 60(3):147-159. PubMed ID: 33099837
[TBL] [Abstract][Full Text] [Related]
23. Spindle Cell Tumors With RET Gene Fusions Exhibit a Morphologic Spectrum Akin to Tumors With NTRK Gene Fusions.
Antonescu CR; Dickson BC; Swanson D; Zhang L; Sung YS; Kao YC; Chang WC; Ran L; Pappo A; Bahrami A; Chi P; Fletcher CD
Am J Surg Pathol; 2019 Oct; 43(10):1384-1391. PubMed ID: 31219820
[TBL] [Abstract][Full Text] [Related]
24. Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?
Fanale D; Corsini LR; Scalia R; Brando C; Cucinella A; Madonia G; Dimino A; Filorizzo C; Barraco N; Bono M; Fiorino A; Magrin L; Sciacchitano R; Perez A; Russo TDB; Pantuso G; Russo A; Bazan V
Crit Rev Oncol Hematol; 2022 Feb; 170():103597. PubMed ID: 35033663
[TBL] [Abstract][Full Text] [Related]
25. Highly sensitive duplex MSI test and BAT40 germline polymorphism.
Kang SY; Kim KM
APMIS; 2021 Oct; 129(10):607-615. PubMed ID: 34342050
[TBL] [Abstract][Full Text] [Related]
26. Current status of biomarker testing in historically rare, high-unmet-need tumors: soft tissue sarcomas and thyroid cancers.
Schroader B; Kong S; Anderson S; Williamson T; Sireci A; Shields K
Expert Rev Anticancer Ther; 2019 Nov; 19(11):929-938. PubMed ID: 31622558
[No Abstract] [Full Text] [Related]
27. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
[TBL] [Abstract][Full Text] [Related]
28. Concordance analysis of microsatellite instability status between polymerase chain reaction based testing and next generation sequencing for solid tumors.
Shimozaki K; Hayashi H; Tanishima S; Horie S; Chida A; Tsugaru K; Togasaki K; Kawasaki K; Aimono E; Hirata K; Nishihara H; Kanai T; Hamamoto Y
Sci Rep; 2021 Oct; 11(1):20003. PubMed ID: 34625576
[TBL] [Abstract][Full Text] [Related]
29. Tumor-Type Agnostic, Targeted Therapies: BRAF Inhibitors Join the Group.
Vranic S; Basu GD; Hall DW; Gatalica Z
Acta Med Acad; 2022 Dec; 51(3):217-231. PubMed ID: 36799315
[TBL] [Abstract][Full Text] [Related]
30. Uterine Cervical Sarcoma With a Novel RET-SPECC1L Fusion in an Adult: A Case Which Expands the Homology Between RET-rearranged and NTRK-rearranged Tumors.
Weisman PS; Altinok M; Carballo EV; Kushner DM; Kram JJF; Ladanyi M; Chiang S; Buehler D; Dickson Michelson EL
Am J Surg Pathol; 2020 Apr; 44(4):567-570. PubMed ID: 31917708
[No Abstract] [Full Text] [Related]
31. Japan society of clinical oncology/Japanese society of medical oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese society of pediatric hematology/oncology.
Naito Y; Mishima S; Akagi K; Igarashi A; Ikeda M; Okano S; Kato S; Takano T; Tsuchihara K; Terashima K; Nishihara H; Nishiyama H; Hiyama E; Hirasawa A; Hosoi H; Maeda O; Yatabe Y; Okamoto W; Ono S; Kajiyama H; Nagashima F; Hatanaka Y; Miyachi M; Kodera Y; Yoshino T; Taniguchi H
Int J Clin Oncol; 2020 Mar; 25(3):403-417. PubMed ID: 31974683
[TBL] [Abstract][Full Text] [Related]
32. Integration of genomic copy number variations and chemotherapy-response biomarkers in pediatric sarcoma.
Cheng L; Pandya PH; Liu E; Chandra P; Wang L; Murray ME; Carter J; Ferguson M; Saadatzadeh MR; Bijangi-Visheshsaraei K; Marshall M; Li L; Pollok KE; Renbarger JL
BMC Med Genomics; 2019 Jan; 12(Suppl 1):23. PubMed ID: 30704460
[TBL] [Abstract][Full Text] [Related]
33. [Tyrosine kinases in soft tissue tumors].
Knösel T; Kampmann E; Kirchner T; Altendorf-Hofmann A
Pathologe; 2014 Nov; 35 Suppl 2():198-201. PubMed ID: 25193679
[TBL] [Abstract][Full Text] [Related]
34. Pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection.
Brozos-Vázquez E; Toledano-Fonseca M; Costa-Fraga N; García-Ortiz MV; Díaz-Lagares Á; Rodríguez-Ariza A; Aranda E; López-López R
Cancer Treat Rev; 2024 Apr; 125():102719. PubMed ID: 38490088
[TBL] [Abstract][Full Text] [Related]
35. [The application of target-based tissue-agnostic therapy in the treatment of lung cancer].
Peták I
Magy Onkol; 2020 Sep; 64(3):206-215. PubMed ID: 32966351
[TBL] [Abstract][Full Text] [Related]
36. Agnostic Administration of Targeted Anticancer Drugs: Looking for a Balance between Hype and Caution.
Aleksakhina SN; Ivantsov AO; Imyanitov EN
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612902
[TBL] [Abstract][Full Text] [Related]
37. Paediatric and adult soft tissue sarcomas with NTRK1 gene fusions: a subset of spindle cell sarcomas unified by a prominent myopericytic/haemangiopericytic pattern.
Haller F; Knopf J; Ackermann A; Bieg M; Kleinheinz K; Schlesner M; Moskalev EA; Will R; Satir AA; Abdelmagid IE; Giedl J; Carbon R; Rompel O; Hartmann A; Wiemann S; Metzler M; Agaimy A
J Pathol; 2016 Apr; 238(5):700-10. PubMed ID: 26863915
[TBL] [Abstract][Full Text] [Related]
38. MSI-High RAS-BRAF wild-type colorectal adenocarcinomas with MLH1 loss have a high frequency of targetable oncogenic gene fusions whose diagnoses are feasible using methods easy-to-implement in pathology laboratories.
Bocciarelli C; Caumont C; Samaison L; Cariou M; Aline-Fardin A; Doucet L; Roudié J; Terris B; Merlio JP; Marcorelles P; Cappellen D; Uguen A
Hum Pathol; 2021 Aug; 114():99-109. PubMed ID: 34019865
[TBL] [Abstract][Full Text] [Related]
39. Genomic and transcriptomic characterization of heterogeneous immune subgroups of microsatellite instability-high colorectal cancers.
Kim JH; Seo MK; Lee JA; Yoo SY; Oh HJ; Kang H; Cho NY; Bae JM; Kang GH; Kim S
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34903553
[TBL] [Abstract][Full Text] [Related]
40. Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma.
Gounder MM; Agaram NP; Trabucco SE; Robinson V; Ferraro RA; Millis SZ; Krishnan A; Lee J; Attia S; Abida W; Drilon A; Chi P; Angelo SP; Dickson MA; Keohan ML; Kelly CM; Agulnik M; Chawla SP; Choy E; Chugh R; Meyer CF; Myer PA; Moore JL; Okimoto RA; Pollock RE; Ravi V; Singh AS; Somaiah N; Wagner AJ; Healey JH; Frampton GM; Venstrom JM; Ross JS; Ladanyi M; Singer S; Brennan MF; Schwartz GK; Lazar AJ; Thomas DM; Maki RG; Tap WD; Ali SM; Jin DX
Nat Commun; 2022 Jun; 13(1):3406. PubMed ID: 35705558
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
